Publications by authors named "Emily Feld"

Claim this Profile
U
Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous Toxicities.
Ian Nykaza, Stephen W Dusza, Jonathan E Rosenberg, Gopa Iyer, Emily Feld

JAMA Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Emily Feld, Darren R Feldman

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
Daniel J Lee, Ryan Hausler, Anh N Le, Gregory Kelly, Jacquelyn Powers, Emily Feld

Eur Urol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Natural Language Processing-Assisted Extraction System for Gleason Scores: Development and Usability Study.
Shun Yu, Anh Le, Emily Feld, Emily Schriver, Peter Gabriel, Michael Feldman

JMIR Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Recall Myositis After Carboplatin/Docetaxel Chemotherapy.
Hann-Hsiang Chao, Emily K Feld, Vivek Narayan, Ronnie Sebro, Joshua A Jones

Pract Radiat Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis.
Ravi B Parikh, Emily K Feld, Matthew D Galsky, Blythe Js Adamson, Aaron B Cohen

Future Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Emily Feld, Joanna Harton, Neal J Meropol, Blythe J S Adamson, Aaron Cohen

Eur Urol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palliative Care Referrals for Advanced Non-small-cell Lung Cancer (NSCLC): Patient and Provider Attitudes and Practices.
Emily Feld, Eric K Singhi, Sharon Phillips, Li-Ching Huang, Yu Shyr

Clin Lung Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy in melanoma.
Emily Feld, Tara C Mitchell

Immunotherapy· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy.
Emily H Castellanos, Emily Feld, Monica V Estrada, Melinda E Sanders, Pierre P Massion

JCO Precis Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.
Emily Feld, Leora Horn

Onco Targets Ther· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.
Emily Castellanos, Emily Feld, Leora Horn

J Thorac Oncol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
Douglas B Johnson, Eirini Pectasides, Emily Feld, Fei Ye, Shilin Zhao

J Immunother· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PD-L1 for non-small-cell lung cancer.
Emily Feld, Leora Horn

Immunotherapy· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Douglas B Johnson, Monica V Estrada, Roberto Salgado, Violeta Sanchez, Deon B Doxie, Emily Feld

Nat Commun· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis